-
1.发明授权Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers 有权针对P-糖蛋白170的治疗性疫苗用于抑制癌症治疗中的多药耐药性公开(公告)号：US08409580B2
公开(公告)日：2013-04-02
申请号：US12870893
申请日：2010-08-30
CPC分类号： A61K39/0005 , A61K39/0011 , A61K2039/55505 , A61K2039/55555 , A61K2039/6018
摘要： The invention relates to an immunogenic composition which comprises, firstly, a carrier and, secondly, as antigenic structure, conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein, each peptide being combined with several molecules of fatty acid containing a carbon chain of between C12 and C24 so as to allow, under suitable administration conditions, the induction of anti-P-170 antibodies.The invention relates to said composition for defining means for treating multidrug resistances.
摘要翻译： 本发明涉及免疫原性组合物，其首先包括载体，其次，作为抗原结构，包含衍生自P-170蛋白的细胞外环的至少一种肽的全部或部分氨基酸序列的缀合物，各自 肽与几个含有C12和C24之间的碳链的脂肪酸分子组合，以便在合适的施用条件下允许诱导抗P-170抗体。 本发明涉及用于定义用于治疗多药耐药性的装置的所述组合物。
-
2.发明申请THERAPEUTIC VACCINE TARGETED AGAINST P-GLYCOPROTEIN 170 FOR INHIBITING MULTIDRUG RESISTANCE IN THE TREATMENT OF CANCERS 审中-公开针对P-GLYCOPROTEIN 170针对抑制癌症治疗耐多药耐药性的治疗性酒精公开(公告)号：US20080026995A1
公开(公告)日：2008-01-31
申请号：US11550788
申请日：2006-10-18
CPC分类号： G01N33/57484 , A61K38/00 , A61K39/0005 , A61K39/0011 , A61K47/64 , A61K47/645 , A61K47/65 , A61K2039/55505 , A61K2039/55555 , A61K2039/6018 , C07K14/705 , G01N2400/00
摘要： The invention relates to conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein. The peptide may be covalently attached to spacers which may be polyethyleneglycol (PEG), polyglycine, polylysine or any polymer chain suitable for human use and is coupled at its free end to a phospholipids, e.g., phosphatidylethanolamine or any other chemically suitable phospholipid.
摘要翻译： 本发明涉及包含衍生自P-170蛋白的细胞外环的至少一种肽的全部或部分氨基酸序列的缀合物。 肽可以共价连接到可以是聚乙二醇（PEG），聚甘氨酸，聚赖氨酸或适于人类使用的任何聚合物链的间隔物上，并且其自由端与磷脂例如磷脂酰乙醇胺或任何其它化学上合适的磷脂偶联。
-
3.发明授权Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers 有权针对P-糖蛋白170的治疗性疫苗用于抑制癌症治疗中的多药耐药性公开(公告)号：US07807171B2
公开(公告)日：2010-10-05
申请号：US10902276
申请日：2004-07-30
IPC分类号： A61K38/00
CPC分类号： A61K39/0005 , A61K39/0011 , A61K2039/55505 , A61K2039/55555 , A61K2039/6018
摘要： The invention relates to an immunogenic composition which comprises, firstly, a carrier and, secondly, as antigenic structure, conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein, each peptide being combined with several molecules of fatty acid containing a carbon chain of between C12 and C24 so as to allow, under suitable administration conditions, the induction of anti-P-170 antibodies.The invention relates to said composition for defining means for treating multidrug resistances.
摘要翻译： 本发明涉及免疫原性组合物，其首先包括载体，其次，作为抗原结构，包含衍生自P-170蛋白的细胞外环的至少一种肽的全部或部分氨基酸序列的缀合物，各自 肽与几个含有C12和C24之间的碳链的脂肪酸分子组合，以便在合适的施用条件下允许诱导抗P-170抗体。 本发明涉及用于定义用于治疗多药耐药性的装置的所述组合物。
-
4.发明申请Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers 有权针对P-糖蛋白170的治疗性疫苗用于抑制癌症治疗中的多药耐药性公开(公告)号：US20110064795A1
公开(公告)日：2011-03-17
申请号：US12870893
申请日：2010-08-30
CPC分类号： A61K39/0005 , A61K39/0011 , A61K2039/55505 , A61K2039/55555 , A61K2039/6018
摘要： The invention relates to an immunogenic composition which comprises, firstly, a carrier and, secondly, as antigenic structure, conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein, each peptide being combined with several molecules of fatty acid containing a carbon chain of between C12 and C24 so as to allow, under suitable administration conditions, the induction of anti-P-170 antibodies.
摘要翻译： 本发明涉及免疫原性组合物，其首先包括载体，其次，作为抗原结构，包含衍生自P-170蛋白的细胞外环的至少一种肽的全部或部分氨基酸序列的缀合物，各自 肽与几个含有C12和C24之间的碳链的脂肪酸分子组合，以便在合适的施用条件下允许诱导抗P-170抗体。
-
-
-
搜索结果
4 条记录 (耗时 0.022 秒)
